EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Heart Failure Etiology and 6-Month Cardiorenal Recovery Patterns After Early In-Hospital SGLT2 Inhibitor Initiation in HFrEF: A Prospective Real-World Cohort

Marija Radić iD, Ivana Jurin iD, Fran Rode, Luka Šimunović iD, Petra Kolundžić, Irzal Hadžibegović iD, Šime Manola iD, Petra Vitlov, Vanja Ivanović Mihajlović, Danijela Grizelj, Hrvoje Falak iD, Mario Udovičić und 1 weitere

Medicina · 24.05.2026 · 62 (6) · 1017

DOI: 10.3390/medicina62061017 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medicina, online erschienen am 24.05.2026. Verfasst von Marija Radić und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Diseases, University hospital Dubrava, 10000 Zagreb, Croatia. Hauptthemen laut MEDLINE: Heart Failure, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SGLT2 inhibitors improve outcomes in heart failure with reduced ejection fraction (HFrEF), but whether early recovery patterns after initiation differ according to HF etiology in real-world practice remains uncertain.

Objective

To evaluate whether ischemic versus non-ischemic etiology is associated with different 6-month cardiac, renal, biomarker, and exploratory metabolic trajectories after early in-hospital SGLT2 inhibitor initiation in HFrEF. Materials and Methods: In this prospective single-center observational cohort (2022–2025), consecutive adults hospitalized with first-presentation acute HFrEF who initiated empagliflozin or dapagliflozin within 48 h of admission were enrolled. Patients were classified as having ischemic cardiomyopathy (ICM) or non-ischemic cardiomyopathy (NICM). The primary analytic cohort included patients with paired baseline and 6-month echocardiography. The primary outcome was change in left ventricular ejection fraction (LVEF); eGFR and NT-proBNP were secondary outcomes. Exploratory metabolic/laboratory variables were summarized descriptively using paired available-case follow-up. The study was approved by the institutional ethics committee and registered in ClinicalTrials.gov under the CaRD registry framework (NCT06090591).

Results

The paired 6-month echocardiographic analytic cohort comprised 241 patients who survived to reassessment (ICM n = 90; NICM n = 151). NICM showed greater improvement in LVEF than ICM (ΔLVEF +10% [IQR 0–18] vs. +5% [IQR 0–12]; p = 0.049) and a more favorable eGFR trajectory (ΔeGFR 0.30 [IQR −5.90 to 6.60] vs. −2.70 [IQR −12.60 to 3.40] mL/min/1.73 m2; p = 0.038). NT-proBNP declined substantially in both groups, with no between-group difference in change magnitude (p = 0.845), although 6-month values remained higher in ICM (p = 0.034). However, after multivariable adjustment, ischemic etiology was no longer independently associated with 6-month LVEF or eGFR outcomes. Exploratory metabolic findings varied descriptively by etiology but should be interpreted cautiously because follow-up completeness and background treatment intensity varied across variables.

Conclusions

In this real-world cohort of patients with HFrEF who initiated SGLT2 inhibitors during hospitalization, HF etiology was associated with different short-term cardiorenal recovery patterns, whereas NT-proBNP reduction was similar across groups. These findings characterize etiology-related recovery within a treated cohort rather than differential SGLT2 inhibitor efficacy and should therefore be considered as hypothesis-generating.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureSodium-Glucose Transporter 2 InhibitorsHumansFemaleProspective StudiesMaleMiddle AgedAgedCohort StudiesStroke VolumeEchocardiographyBenzhydryl CompoundsBiomarkersNatriuretic Peptide, BrainGlucosides

Stichwörter der Autor:innen

NT-proBNPheart failure with reduced ejection fractionischemic cardiomyopathynon-ischemic cardiomyopathyreal-world cohortrenal functionreverse remodelingsodium–glucose cotransporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsBiomarkersNatriuretic Peptide, BrainGlucosidesdapagliflozin

Autor:innen und Institutionen

  • Department of Cardiovascular Diseases, University hospital Dubrava, 10000 Zagreb, Croatia.
  • Department of Orthodontics, School of Dental Medicine, University of Zagreb, Gundulićeva 5, 10000 Zagreb, Croatia.
  • School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
  • Faculty of Dental Medicine and Health Care, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
  • Department of Cardiology, University Hospital Merkur, Zajceva 19, 10000 Zagreb, Croatia.

ORCID-Profile: Marija Radić, Ivana Jurin, Luka Šimunović, Irzal Hadžibegović, Šime Manola, Hrvoje Falak

Zitieren

APA

Radić, M., Jurin, I., Rode, F., Šimunović, L., Kolundžić, P., Hadžibegović, I., Manola, Š., Vitlov, P., Ivanović Mihajlović, V., Grizelj, D., Falak, H., Udovičić, M., & Letilović, T. (2026). Heart Failure Etiology and 6-Month Cardiorenal Recovery Patterns After Early In-Hospital SGLT2 Inhibitor Initiation in HFrEF: A Prospective Real-World Cohort. Medicina, 62(6), 1017. https://doi.org/10.3390/medicina62061017

Vancouver

Radić M, Jurin I, Rode F, Šimunović L, Kolundžić P, Hadžibegović I, et al. Heart Failure Etiology and 6-Month Cardiorenal Recovery Patterns After Early In-Hospital SGLT2 Inhibitor Initiation in HFrEF: A Prospective Real-World Cohort. Medicina. 2026;62(6):1017. doi:10.3390/medicina62061017

BibTeX
@article{Radi2026,
  author = {Radić, Marija and Jurin, Ivana and Rode, Fran and Šimunović, Luka and Kolundžić, Petra and Hadžibegović, Irzal and Manola, Šime and Vitlov, Petra and Ivanović Mihajlović, Vanja and Grizelj, Danijela and Falak, Hrvoje and Udovičić, Mario and Letilović, Tomislav},
  title = {Heart Failure Etiology and 6-Month Cardiorenal Recovery Patterns After Early In-Hospital SGLT2 Inhibitor Initiation in HFrEF: A Prospective Real-World Cohort},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {6},
  pages = {1017},
  doi = {10.3390/medicina62061017}
}
Kostenlos starten →